SOST and osteoporosis: Indeed, targeting sclerostin protein with neutralizing antibodies is incredibly effective at increasing bone mass, and Romosozumab, a humanized monoclonal antibody targeting sclerostin, has been FDA approved to treat osteoporosis in post-menopausal women at a high risk for fracture (McClung, 2017; Bandeira et al., 2017).